Midday movers: Nvidia, Coinbase fall; Unilever rises

Coinbase (COIN) price target raised at Needham on strong crypto volumes

The Coinbase (NASDAQ: COIN) price target was raised to $275 from $220 per share at Needham & Company on Thursday, with the firm maintaining a Buy rating on the stock.

The investment firm believes the sell-side is missing the extent to which retail has... More

International Flavors & Fragrances (IFF) PT Raised to $85 at BofA Securities

BofA Securities analyst Matthew DeYoe raised the price target on International Flavors & Fragrances (NYSE: IFF) to $85.00 (from $83.00) while maintaining a Neutral rating.

The analyst comments "Yesterday, IFF announced an agreement to sell its Pharma Solutions business to Roquette for $2.85bn. The transaction reflects a... More

BofA Review NVIDIA (NVDA) GTC, 'AI dominance continues in training + inference'

BofA Securities analyst Vivek Arya reiterated a Buy rating and $1,100.00 price target on NVIDIA (NASDAQ: NVDA).

The analyst comments "Maintain Buy, $1100 PO and top compute pick following financial analyst Q&A session at GTC 2024 (see our initial GTC takeaways report). Overall,... More

XPeng (XPEV) PT Lowered to $18.60 at Jefferies

Jefferies analyst Alexious Lee lowered the price target on XPeng (NYSE: XPEV) to $18.60 (from $25.30) while maintaining a Buy rating.

The analyst comments "XPeng reported 4Q23 results with rev up 153.9% YoY and 53% QoQ to RMB13.1bn and net loss narrowed by... More

XPeng (XPEV) PT Lowered to $13.50 at BofA Securities

BofA Securities analyst Ming Hsun Lee lowered the price target on XPeng (NYSE: XPEV) to $13.50 (from $14.80) while maintaining a Buy rating.

The analyst comments "Xpeng reported 4Q23 results and hosted conference call: 4Q23 revenue came in at RMB13bn, up 154% YoY / 53%... More

XPeng (XPEV) PT Lowered to $15 at US Tiger Securities

US Tiger Securities analyst Bo Pei lowered the price target on XPeng (NYSE: XPEV) to $15.00 (from $20.00) while maintaining a Buy rating.

The analyst comments "We are maintaining our BUY rating but decreasing PT to $15 (was $20) after XPEV beat 4Q margins, but with 1Q guidance implying weak seasonality and intense industry competition. With 4Q deliveries (60,158) preannounced, investors primarily focused on 4Q margin, 1Q guidance and '24 outlook. Vehicle margin was 4.1% in 4Q, down 161bps y/y but up 1,011bps... More

NVIDIA (NVDA) PT Raised to $950 at Argus

Argus analyst Jim Kelleher raised the price target on NVIDIA (NASDAQ: NVDA) to $950.00 (from $850.00) while maintaining a Buy rating.

The analyst comments "In summary, Nvidia continues to develop ever more powerful generative AI tools and is now powering trillion-parameter multi-mode models. New... More

NVIDIA (NVDA) PT Raised to $1,030 at Citi

Citi analyst Atif Malik raised the price target on NVIDIA (NASDAQ: NVDA) to $1,030.00 (from $820.00) while maintaining a Buy rating.

The analyst comments "We came away from the first two days of GTC more positive in NVIDIAs ability to vertically integrate its computing,... More

International Flavors & Fragrances (IFF) PT Raised to $100 at Deutsche Bank

Deutsche Bank analyst David Begleiter raised the price target on International Flavors & Fragrances (NYSE: IFF) to $100.00 (from $90.00) while maintaining a Buy rating.

The analyst comments "With the sale of Pharma Solutions, IFF has taken a major step in reducing its leverage below 3x and thus removing the leverage overhang on the shares that has existed since the... More

NVIDIA (NVDA) PT Raised to $850 at Deutsche Bank, Remains Sidelined

Deutsche Bank analyst Ross Seymore raised the price target on NVIDIA (NASDAQ: NVDA) to $850.00 (from $720.00) while maintaining a Hold rating.

The analyst comments "At this years GTC, NVDA reinforced its reputation as the top enabler of AI innovation, with its influence both broad (end customers span applications from 6G to drug discovery to robots/cobots) and deep (NVDA products increasingly addressing the vertical... More

Morgan Stanley Opens Research Tactical Idea on XPeng (XPEV)

Morgan Stanley analyst Tim Hsiao reiterated an Overweight rating and $18.00 price target on XPeng (NYSE: XPEV).

The analyst comments "We believe the share price will rise in absolute terms over the next 45 days. This is because the stock has traded off recently,... More

Morgan Stanley Downgrades Fusion Pharmaceuticals (FUSN) to Equalweight

Morgan Stanley analyst Matthew Harrison downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Overweight to Equalweight with a price target of $21.00 (from $10.00).

The analyst comments "Fusion to be acquired by AstraZeneca for $21/share in cash payable at deal closing (vs. 03/18 closing price of $10.64),... More

Options expert says AI rally 'unlikely' a bubble

(Updated - March 20, 2024 1:09 PM EDT)

Brett Friedman, a managing partner at Winhall Risk Analytics and a contributor to OptionMetrics, told Investing.com this week that he feels the rally in artificial intelligence stocks is "unlikely" a bubble.

"From an options point of view, it seems unlikely, currently," declared Friedman. "Option metrics that would indicate a bubble forming -- the trend of implied... More

AMD stock sinks on Nvidia's new chip

Shares of AMD (NASDAQ: AMD) are down more than 6% on Tuesday after NVIDIA (NASDAQ: NVDA) revealed its latest generation of artificial intelligence chips, Blackwell.

NVIDIA CEO Jensen Huang announced the new chips at the company's... More

International Flavors & Fragrances (IFF) PT Raised to $85 at Stifel

Stifel analyst Mark Astachan raised the price target on International Flavors & Fragrances (NYSE: IFF) to $85.00 (from $80.00) while maintaining a Hold rating after selling its Pharma business for up to $2.85 billion.

The analyst commented, "IFF announced the sale of its Pharma business for up to $2.85bn,... More

Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to Hold

Jefferies analyst Suji Jeong downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Buy to Hold with a price target of $21.00 (from $10.00).

The analyst comments "AZN will acquire FUSN's radiopharma platform for $21/sh in cash (~$2B upfront), plus another $3/sh CVR (~$400M value) upon... More

CFRA Comments on NVIDIA (NVDA) Conference

CFRA analyst Angelo Zino reiterated a Buy rating and $1,000.00 price target on NVIDIA (NASDAQ: NVDA)

The analyst comments "
We took away three important messages from Jensen Huang's GTC keynote. First, hardware revenue has more upside, as NVDA's Blackwell GPU (B200) will command higher... More